Gossamer Bio, Inc. — Form SCHEDULE 13D/A
Filed July 24, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▼ Likely negative
significance 28/100
What the filing says
Between July 2–24, 2026, D.E. Shaw-affiliated entities (Valence Portfolios, Cogence Advisors, and DESIM Advisors) sold approximately 5,945,982 shares of Gossamer Bio common stock at prices ranging from $0.1302 to $0.1910 per share. The aggregate sale value is approximately $908,000–$1,134,000 (roughly 0.34%–0.42% of Gossamer's $270.8M market cap). The filing documents a joint reporting arrangement by D.E. Shaw Co., L.P., D.E. Shaw Co., L.L.C., Valence Portfolios, L.L.C., and David E. Shaw.
Why this rating
Coordinated insider selling of ~$1M (0.4% of market cap) signals potential loss of confidence; however, sale is modest in absolute and relative terms and routine for hedge funds.
See more from July 24, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.